Glaukos Corp (GKOS) cash flow statement

NYSE · Health Care

$243.25 -0.67% Close Nov 17, 2026 Live

TrendArc score 50 of 100 · Health 3.0 · Momentum 9.5 · Moat 3.1 · scored Nov 17, 2026 · How the score works

Free cash flow, fiscal year to December 31, 2025

-$39 million

against -$68 million the year before

In the fiscal year to December 2025, Glaukos used $15 million in its operations and spent $24 million on capital spending, a free cash flow of -$39 million. That was -7.7% of revenue, against -17.6% the year before. Over the last four quarters, to September 30, 2026, it was $36 million.

What stands out

  • Diluted shares outstanding rose 28.5% over the five fiscal years to December 2025.

Each sentence is written by a fixed rule from the figures on this page.

Free cash flow and net income, the last 10 fiscal years

-$200M-$150M-$100M-$50.0M$50.0M$100M$150M$200M2016201720182019202020212022202320242025$6.03MFree cash flow -$39.1MNet income -$188M-$200M-$150M-$100M-$50.0M$50.0M$100M$150M$200M20172019202120232025Free cash flow -$39.1MNet income -$188M

Fiscal years, each labelled by the calendar year it ended in. Every figure is in the statement below.

Cash flow statement, the last 10 fiscal years

In millions of US dollars. Each column is a fiscal year, named by the month it ended; the first column adds up the last four quarters. Cash paid out is a negative number.
Fiscal year toLast 4 quarters
to Sep 2026
Dec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Operating activities
Net income-188-146-135-99-50-12015-1305
Depreciation and amortisation42403836343510655
Stock-based pay836350443930433926189
Working capital and other items67-5-5-81019-6503-6
Cash from operations48-15-61-58-3325-230192612
Investing activities
Capital spending-12-24-6-20-30-48-7-5-10-6-6
Businesses bought and sold, net-120000050000
Investments bought and sold, net-35573876-8-1960-15-5-20
Other investing-6-3-3-1-2-2-2-1-10
Cash from investing-78481445-58-20543-26-12-26
Financing activities
Debt issued or repaid, net-151-10-1242-2200-10
Shares issued less bought back4421471993124182258
Dividends paid00000000000
Other financing-8-7-3-39-4-6-100
Cash from financing129215639263-10225-2
Exchange rate effect1-31-1-200000
Net change in cash-8075-2716434331418-15
Free cash flow
Free cash flow36-39-68-78-63-23-30-59206
Free cash flow margin5.2%-7.7%-17.6%-24.8%-22.3%-7.8%-13.3%-2.1%4.7%12.4%5.3%
Free cash flow per share-$0.68-$1.28-$1.61-$1.33-$0.50-$0.67-$0.12$0.24——
Free cash flow less stock-based pay-102-118-122-102-53-73-45-172-3

Shares issued less bought back is the cash from shares sold less the cash paid for shares bought back (negative when more was bought back), and includes tax withheld when employees' shares vest. Working capital and other items is cash from operations less net income, depreciation and amortisation, and stock-based pay (calculated by TrendArc). Company filings as standardised by Tiingo; calculations by TrendArc. Rebuilt nightly.

Glaukos against its peers

CompanyFiscal year toFree cash flowFree cash flow margin
ExelixisEXEL Dec 2025$876M37.7%
RevvityRVTY Dec 2025$509M17.8%
Charles River LaboratoriesCRL Dec 2025$518M12.9%
Cooper Companies (The)COO Oct 2025$434M10.6%
Brightspring Health ServicesBTSG Dec 2025$395M3.1%
Baxter InternationalBAX Dec 2025$323M2.9%
SolventumSOLV Dec 2025-$10.0M-0.1%
GlaukosGKOS Dec 2025-$39.1M-7.7%
Bridgebio PharmaBBIO Dec 2025-$447M-89.0%
Peer median6.8%

Each company's newest fiscal year; some end in other months. The peers are the stock card's peer group.

Next

Follow Glaukos with a free account.

A watchlist, price alerts and saved chart layouts. No card needed.

Sign up free

No forecast, no recommendation. This page describes Glaukos Corp from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.